BRCA1 and ovarian carcinoma: In epithelial ovarian cancer, Karakashev et al. demonstrated that the BETi JQ1 synergised with the PARPi Olaparib in BRCA1/2 wild-type models, and that BETi could also re-sensitise PARPi-resistant BRCA-mutant cells by suppressing WEE1 and TOPBP1 expression (Karakashev et al., 2017).